Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Linmiao Jiang

8PUBLICATIONS
53CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersEpigenetics (incl. genome methylation and epigenomics)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

Sort by Publication Date:
|Jul 14, 2026
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.

|Nov 03, 2025
Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.

Mouhamad Khouja, Elisa Genuardi, Simone Ferrero

|Oct 23, 2024
Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network.

Linmiao Jiang, Martin Dreyling, Olivier Hermine

|Sep 16, 2024
Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials.

Mouhamad Khouja, Linmiao Jiang, Karol Pal

|Apr 27, 2024
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.

Luca Fischer, Linmiao Jiang, Jan Dürig

|Nov 22, 2023
Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial.

Eva Hoster, Marie-Hélène Delfau-Larue, Elizabeth Macintyre

Pageof 2

Frequent Collaborators

8 joint publications

Eva Hoster

5 joint publications

Christiane Pott

3 joint publications

Martin Dreyling

2 joint publications

Stefan Wirths

2 joint publications

Jan Walewski

2 joint publications

Catherine Thieblemont

2 joint publications

Gilles Salles

2 joint publications

Simone Ferrero

2 joint publications

Mats Jerkeman

2 joint publications

Wolfram Klapper

Frequent Collaborators

8 joint publications

Eva Hoster

5 joint publications

Christiane Pott

3 joint publications

Martin Dreyling

2 joint publications

Stefan Wirths